Skip to Content
Merck

Personalized Mapping of Drug Metabolism by the Human Gut Microbiome.

Cell (2020-06-12)
Bahar Javdan, Jaime G Lopez, Pranatchareeya Chankhamjon, Ying-Chiang J Lee, Raphaella Hull, Qihao Wu, Xiaojuan Wang, Seema Chatterjee, Mohamed S Donia
ABSTRACT

The human gut microbiome harbors hundreds of bacterial species with diverse biochemical capabilities. Dozens of drugs have been shown to be metabolized by single isolates from the gut microbiome, but the extent of this phenomenon is rarely explored in the context of microbial communities. Here, we develop a quantitative experimental framework for mapping the ability of the human gut microbiome to metabolize small molecule drugs: Microbiome-Derived Metabolism (MDM)-Screen. Included are a batch culturing system for sustained growth of subject-specific gut microbial communities, an ex vivo drug metabolism screen, and targeted and untargeted functional metagenomic screens to identify microbiome-encoded genes responsible for specific metabolic events. Our framework identifies novel drug-microbiome interactions that vary between individuals and demonstrates how the gut microbiome might be used in drug development and personalized medicine.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Nicardipine hydrochloride, powder, ≥98%
Supelco
Metronidazole, analytical standard
Sigma-Aldrich
5-Fluoro-5′-deoxyuridine
Sigma-Aldrich
Misoprostol, ≥99% (HPLC)
Sigma-Aldrich
Hydrocortisone, ≥98% (HPLC)
Supelco
Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Mycophenolate mofetil, ≥98% (HPLC)
Supelco
Capecitabine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Aspartame, analytical standard
Sigma-Aldrich
Mycophenolic acid, ≥98%
Sigma-Aldrich
Clofazimine
Sigma-Aldrich
Ketoconazole, 99.0-101.0% (EP, titration)
Sigma-Aldrich
Allopurinol, xanthine oxidase inhibitor
Supelco
Sulfamethoxazole
Supelco
Bisacodyl, analytical standard, for drug analysis
Sigma-Aldrich
Misoprostol free acid, ≥90%